Practical consensus recommendations on ovarian suppression in early breast cancer (adjuvant)

Abstract Substantial survival benefits exist for patients with early-stage breast cancer who undergo treatment with single-modality ovarian suppression, but its value is uncertain. Expert oncologist discussed to determine whether additional benefits exist with ovarian suppression plus multiple adjuvant therapy which provides a new treatment option that reduces the risk of recurrence in early breast cancer. This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at this practical consensus recommendations for the benefit of community oncologists.

[1]  Kevin A. Henry,et al.  Annual Report to the Nation on the Status of Cancer, 1975–2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State , 2015, Journal of the National Cancer Institute.

[2]  A. Giobbie-Hurder,et al.  Adjuvant ovarian suppression in premenopausal breast cancer. , 2015, The New England journal of medicine.

[3]  S. Martino,et al.  Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Giobbie-Hurder,et al.  Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. , 2014, The New England journal of medicine.

[5]  R. Gelber,et al.  Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. , 2013, Breast.

[6]  Ming-Feng Hou,et al.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial , 2013, The Lancet.

[7]  S. Narod.  Breast cancer in young women , 2012, Nature Reviews Clinical Oncology.

[8]  J. Griggs,et al.  American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  N. Wolmark,et al.  Amenorrhea from breast cancer therapy--not a matter of dose. , 2010, The New England journal of medicine.

[10]  A. Shelling.  Premature ovarian failure. , 2010, Reproduction.

[11]  J Cuzick,et al.  Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials , 2007, The Lancet.

[12]  R. Gelber,et al.  Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[14]  R. Calderon-Margalit,et al.  Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: A critical review of the literature , 2004, International journal of cancer.

[15]  F. Esteva.  Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer. , 2004, The oncologist.

[16]  P. Lønning,et al.  A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer* , 2004, The New England journal of medicine.

[17]  E. Perez,et al.  A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. , 2004, The New England journal of medicine.

[18]  J. Robertson,et al.  Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer , 2004, British Journal of Cancer.

[19]  R. Brueggemeier,et al.  Aromatase Inhibitors: New Endocrine Treatment of Breast Cancer , 2004, Seminars in reproductive medicine.

[20]  W. Parulekar,et al.  Ovarian ablation as adjuvant therapy for premenopausal women with breast cancer--another step forward. , 2003, Journal of the National Cancer Institute.

[21]  R. Nahta,et al.  HER-2-targeted therapy: lessons learned and future directions. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  M. Dowsett.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses , 2003 .

[23]  R. Gelber,et al.  Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  L. Rutqvist,et al.  Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J Cuzick,et al.  Overview of the main outcomes in breast-cancer prevention trials , 2003, The Lancet.

[26]  R. Gelber,et al.  Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  E. Dees,et al.  Ovarian ablation as adjuvant therapy for breast cancer. , 2001, Seminars in oncology.

[28]  J. Forbes,et al.  Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer? First results of International Breast Cancer Study Group Trial 11– , 2001 .

[29]  Robert J. Mayer,et al.  National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. , 2001, Journal of the National Cancer Institute.

[30]  P. Sjödén,et al.  Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  F. Cavalli,et al.  Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. , 1998, European journal of cancer.

[32]  S. Martino,et al.  Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  R. Collins,et al.  Ovarian ablation in early breast cancer: overview of the randomised trials , 1996, The Lancet.

[34]  P. Sismondi,et al.  Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  R. Gelber,et al.  Adjuvant therapy for breast cancer: understanding the overview. International Breast Cancer Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Early Breast Cancer Trialists' Collaborative Group.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.

[37]  C. Beattie,et al.  Endocrine profile in breast cancer patients receiving chemotherapy , 1991, Breast Cancer Research and Treatment.

[38]  I. Mittra,et al.  Clinico-pathological features and prognosis of breast cancer in different religious communities in India. , 1990, Indian Journal of Cancer.

[39]  H. Honoré,et al.  Breast cancer in young women. , 1979, British medical journal.

[40]  G. Bonadonna,et al.  Combination chemotherapy as an adjuvant treatment in operable breast cancer. , 1976, The New England journal of medicine.

[41]  B D PETROV,et al.  In Japan … , 1975, Sovetskoe zdravookhranenie.

[42]  C. Redmond,et al.  1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. , 1975, The New England journal of medicine.

[43]  R. Paterson,et al.  Clinical trials in malignant disease. Part II-breast cancer: value of irradiation of the ovaries. , 1959, The Journal of the Faculty of Radiologists. Faculty of Radiologists.

[44]  G. Beatson.  On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases , 1896, Transactions. Medico-Chirurgical Society of Edinburgh.

[45]  F. Cardoso,et al.  First international consensus guidelines for breast cancer in young women (BCY1). , 2014, Breast.

[46]  DNB PDC Gaurav Agarwal MS,et al.  Spectrum of Breast Cancer in Asian Women , 2005, World Journal of Surgery.

[47]  T. Endo,et al.  Current status and goals of mammographic screening for breast cancer in japan , 2004, Breast cancer.

[48]  N. Wolmark,et al.  Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. , 2001, Journal of the National Cancer Institute.

[49]  C. Benz,et al.  Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. , 2000, Drugs.

[50]  T. Powles,et al.  Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.